Hypothalamic Adult Neurogenesis (hAN) has been implicated in regulating energy homeostasis. Adult-generated neurons and adult Neural Stem Cells (aNSCs) in the hypothalamus control food intake and body weight. Conversely, diet-induced obesity (DIO) by high fat diets (HFD) exerts adverse influence on hAN. However, the effects of anti-obesity compounds on hAN are not known. To address this, we administered a lipidized analogue of an anti-obesity neuropeptide, Prolactin Releasing Peptide (PrRP), so-called LiPR, to mice. In the HFD context, LiPR rescued the survival of adult-born hypothalamic neurons and increased the number of aNSCs by reducing their activation. LiPR also rescued the reduction of immature hippocampal neurons and modulated calcium dynamics in iPSC-derived human neurons. In addition, some of these neurogenic effects were exerted by another anti-obesity compound, Liraglutide. These results show for the first time that anti-obesity neuropeptides influence adult neurogenesis and suggest that the neurogenic process can serve as a target of anti-obesity pharmacotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10897398 | PMC |
| http://dx.doi.org/10.1038/s44319-023-00016-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving Recall Accuracy in Sparse Associative Memories That Use Neurogenesis.
Neural Comput
January 2025
Electronics and Computer Science, University of Southampton, Southampton SO17 1BJ, U.K.
The creation of future low-power neuromorphic solutions requires specialist spiking neural network (SNN) algorithms that are optimized for neuromorphic settings. One such algorithmic challenge is the ability to recall learned patterns from their noisy variants. Solutions to this problem may be required to memorize vast numbers of patterns based on limited training data and subsequently recall the patterns in the presence of noise.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Geriatric Research Education and Clinical Center William S. Middleton VA Hospital, Madison, WI, USA.
Background: Brain-derived neurotrophic factor (BDNF)-a key neurotrophin involved in synaptic plasticity, neurogenesis, and neuroprotection-has been shown to mediate sex differences in verbal learning and memory (VLM) ability, but it remains unclear whether this relationship is conditionally dependent upon carriage of the Val66Met polymorphism in the BDNF gene. This study investigates how BDNF carriage influences the mediation of sex differences in VLM scores by plasma BDNF levels in a cohort enriched for AD risk.
Method: Cognitively unimpaired participants in the Wisconsin Registry for Alzheimer's Prevention (WRAP; n=198, age 63.
Background: Older adults with type 2 diabetes (T2D) are more likely to develop Alzheimer's disease (AD) due to impaired brain metabolism. Although the underlying mechanisms of this relationship are largely unknown, lower levels of brain-derived neurotrophic factor (BDNF) -which promotes hippocampal neurogenesis in adulthood- and atrophy of the hippocampus are evident in patients with T2D and dementia, possibly linking the two conditions. The hippocampus is comprised of multiple subfields, each with their respective functions, cellular composition, and age-related sensitivity.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Sorbonne University, GRC n°21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de L'hôpital, F-75013, Paris, France.
Background: Neuropsychiatric symptoms (NPS), including depression and circadian rhythm disruptions, are early non-cognitive markers along the Alzheimer's Disease (AD) continuum. These pathological states are thought to resemble AD pathogenesis, both of which are characterized by a marked decline in adult hippocampal neurogenesis.
Method: 96 elderly participants divided into three groups based on the global depression scale, neuropsychiatric inventory, clinical dementia rating, and mini-mental status examination.
Background: Preclinical investigations in Alzheimer's disease (AD) have highlighted the efficacy of gamma sensory stimulation in mitigating AD-related pathologies. Cognito Therapeutics, Inc. (Cambridge, MA) has designed the Sensory Stimulation System for safe at-home usage, to induce EEG-confirmed gamma oscillations as a potential treatment for AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!